What is FluGen?
FluGen Inc. is a biotechnology firm focused on revolutionizing influenza prevention through its M2SR Vaccine Platform. The company's lead candidate, an intranasal M2SR vaccine, is engineered to elicit a broad immune response, offering protection against both seasonal flu strains and potential viral drifts. FluGen specifically targets high-risk demographics, including the elderly and young children, who are particularly vulnerable to influenza and other respiratory illnesses. The M2SR platform also shows promise for applications against COVID-19 and other respiratory pathogens, positioning FluGen at the forefront of infectious disease defense.
How much funding has FluGen raised?
FluGen has raised a total of $20.4M across 5 funding rounds:
Debt
$3.2M
Other Financing Round
$9.4M
Series A
$2M
Debt
$5.5M
Debt
$234K
Debt (2014): $3.2M, investors not publicly disclosed
Other Financing Round (2015): $9.4M led by Knox Payments, Wisconsin Alumni Research Foundation, Venture Investors, and State of Wisconsin - Investment Board
Series A (2017): $2M supported by State of Wisconsin - Investment Board, Knox Payments, Venture Investors, and Wisconsin Alumni Research Foundation
Debt (2017): $5.5M, investors not publicly disclosed
Debt (2021): $234K backed by PPP
Key Investors in FluGen
State of Wisconsin - Investment Board
The State of Wisconsin Investment Board is a significant institutional investor managing assets for the Wisconsin retirement system and other state funds. Their investment strategy includes public equity, fixed income, and alternative markets, indicating a broad approach to capital allocation.
Venture Investors
Venture Investors Health Fund is a venture capital firm specializing in transformative healthcare innovations, with a focus on university spinouts and early-stage companies aiming to improve patient outcomes.
Wisconsin Alumni Research Foundation
The Wisconsin Alumni Research Foundation (WARF) is a non-profit organization dedicated to managing and commercializing intellectual property from the University of Wisconsin-Madison, supporting scientific research and innovation through patenting, licensing, and investment.
What's next for FluGen?
With the recent influx of major strategic investment, FluGen is poised for accelerated development and market penetration. The enterprise-level funding suggests a focus on scaling manufacturing capabilities, expanding clinical trials, and potentially forging strategic partnerships to bring its advanced influenza vaccine to a global market. The company's commitment to addressing unmet needs in flu prevention, coupled with the platform's versatility for other respiratory viruses, indicates a strong trajectory for future growth and impact in public health.
See full FluGen company page
